These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34324914)

  • 1. Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial.
    Glicksman RM; Loblaw A; Morton G; Szumacher E; Chung HT; Vesprini D; Chu W; Liu SK; Choo R; Deabreu A; Mamedov A; Zhang L; Cheung P
    Radiother Oncol; 2021 Oct; 163():21-31. PubMed ID: 34324914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT).
    Glicksman RM; Loblaw A; Morton G; Vesprini D; Szumacher E; Chung HT; Chu W; Liu SK; Tseng CL; Correa R; Deabreu A; Mamedov A; Zhang L; Cheung P
    Int J Radiat Oncol Biol Phys; 2024 May; 119(1):100-109. PubMed ID: 37979707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderately Hypofractionated Radiotherapy and Androgen Deprivation Therapy for High-risk Localised Prostate Cancer: Predictors of Long-term Biochemical Control and Toxicity.
    Maulik S; Arunsingh M; Arun B; Prasath S; Mallick I
    Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e52-e60. PubMed ID: 34456107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
    Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial.
    Hall WA; Bedi M; Kilari D; Bylow KA; Burfeind J; Johnstone C; Siker M; Currey A; See WA; Nelson A; Johnson S; Straza M; Lawton CAF
    Pract Radiat Oncol; 2021; 11(6):527-533. PubMed ID: 33848618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial.
    Magli A; Moretti E; Tullio A; Giannarini G; Tonetto F; Urpis M; Crespi M; Foti C; Prisco A; Polsinelli M; De Giorgi G; Bravo G; Scalchi P; Trovò M
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):269-276. PubMed ID: 29520019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moderately Hypofractionated Radiotherapy in Node-positive Prostate Cancer.
    Mallick I; Das A; Arunsingh M
    Clin Oncol (R Coll Radiol); 2019 Apr; 31(4):260-264. PubMed ID: 30718087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Results of Moderate Hypofractionation to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer.
    Faria S; Ruo R; Perna M; Cury F; Duclos M; Sarshoghi A; Souhami L
    Pract Radiat Oncol; 2020; 10(6):e514-e520. PubMed ID: 32738465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
    Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience.
    Hegazy MW; Mahmood RI; Al Otaibi MF; Khalil EM
    J Egypt Natl Canc Inst; 2016 Jun; 28(2):101-10. PubMed ID: 27133975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
    Habl G; Katayama S; Uhl M; Kessel KA; Edler L; Debus J; Herfarth K; Sterzing F
    BMC Cancer; 2015 Nov; 15():868. PubMed ID: 26547188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderately hypofractionated salvage radiotherapy in patients with biochemical recurrence of prostate cancer after prostatectomy: long-term results and comparative analysis of two schedules.
    Matrone F; Donofrio A; Fanetti G; Revelant A; Polesel J; Chiovati P; Bortolus R
    Neoplasma; 2022 Dec; 69(6):1425-1436. PubMed ID: 36305692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial.
    Katayama S; Habl G; Kessel K; Edler L; Debus J; Herfarth K; Sterzing F
    BMC Cancer; 2014 Jan; 14():20. PubMed ID: 24422782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty Fraction Prostate Radiotherapy with Intra-prostatic Boost: Results of a Pilot Study.
    Onjukka E; Uzan J; Baker C; Howard L; Nahum A; Syndikus I
    Clin Oncol (R Coll Radiol); 2017 Jan; 29(1):6-14. PubMed ID: 27692920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.